CSL to buy Talecris Biotherapeutics for $3.1 billion

Australian plasma giant CSL will tap several sources to pay for the purchase of the US company, including a $1.5 billion share placement.

CSL yesterday announced that it had signed an agreement to acquire Talecris Biotherapeutics Holdings for $3.1 billion. CSL is an Australian company that focuses on the development and manufacture of vaccines and plasma therapies. It will be purchasing the US manufacturer of plasma-derived protein therapies from two hedge funds รป Cerberus Partners and Ampersand Ventures.

The purchase price values Talecris at an historical adjusted Ebit multiple of 12.7 times, based on the 12 months ending June 30, and an Ebitda...

To continue reading, please login or register for free

Click for more on: csl | merrill lynch | talecris

Print Edition

FinanceAsia Print Edition